Philip Morris International Inc. (NYSE:PM) is one of the stocks that Jim Cramer expressed thoughts on. Expressing their appreciation for the dividend, an investing club member inquired about the stock during the lightning round. Cramer remarked: “It’s actually one of my favorites when it comes to a great stock. It’s just what they make, I can’t bear. It’s actually the greatest performing stock of all time, just so you know.” Philip Morris International Inc. (NYSE:PM) manufactures and sells cigarettes a ...

The Zacks Tobacco industry is facing mounting challenges, including declining cigarette sales – resulting from shifting consumer preferences, inflationary pressures and tightening regulations. Rising health awareness and stricter restrictions on smoking are reducing demand for traditional tobacco products, weighing on the overall industry performance.Despite these headwinds, companies such as Philip Morris International Inc. ((PM), Altria Group, Inc. ((MO) and Turning Point Brands, Inc. ((TPB) are well-posi ...

We came across a bullish thesis on Turning Point Brands, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on TPB. Turning Point Brands, Inc.'s share was trading at $98.02 as of September 25th. TPB’s trailing and forward P/E were 35.01 and 24.75 respectively according to Yahoo Finance. Tilray Brands (TLRY) – Tilray Boosts Revenue Mix with New Cannabis, Wellness, and Beverage Products Copyright: nilswey / 123RF Stock Photo TPB Holdings (TPB) occupies ...

Key Takeaways Altria's on! reached 8.7% U.S. oral tobacco share, up 0.7 points from the prior year.The brand's 26.5% shipment jump to 52.1M cans drove segment profit growth.Helix drives on!'s growth through event marketing and rising brand awareness.Altria Group, Inc.’s ((MO) investment in the smoke-free future is anchored by its on! nicotine pouches, which were the primary driver of growth in the oral tobacco products segment for the second quarter of 2025. The brand’s strong performance pushed its retail ...

Core Insights - Altria Group, Inc. and Philip Morris International Inc. are leading companies in the global tobacco industry, with market capitalizations of approximately $109.5 billion and $255.3 billion respectively [1][2] - Both companies are heavily investing in next-generation products to adapt to declining cigarette volumes and increasing demand for smoke-free alternatives [3] Altria Group, Inc. (MO) - Altria's strong pricing power has allowed it to offset declines in cigarette volumes, with a net price realization of 10% in the smokeable products segment leading to adjusted operating companies income (OCI) growth of 4.2% in Q2 2025 [4] - The oral tobacco segment saw a 10.9% increase in adjusted OCI, with segment margins expanding 310 basis points to 68.7%, driven by the success of the on! nicotine pouch brand [5] - Adjusted earnings per share increased by 8.3% year over year to $1.44, supported by strong adjusted OCI growth and share repurchases, with Marlboro holding a 59.5% share in the premium category [6] - Domestic cigarette volumes fell 10.2% in Q2 2025, indicating ongoing industry declines and competitive pressure from flavored disposable e-vapor products [7] Philip Morris International Inc. (PM) - Philip Morris' smoke-free products accounted for 41% of total net revenues in Q2 2025, reflecting a 15.2% year-over-year increase, with IQOS, ZYN, and VEEV driving this growth [11] - Combustible net revenues advanced 2.1% in the quarter, supported by strong pricing power, while gross profit increased by 5% [12] - The company achieved over $500 million in gross cost savings in the first half of 2025, contributing to meaningful margin expansion [13] - Traditional cigarette volumes fell 1.5% year over year to 155.2 billion units, with management projecting a full-year decline of 2% [14] Financial Performance Comparison - The Zacks Consensus Estimate for Altria's 2025 EPS is $5.39, indicating a year-over-year increase of 5.3%, while Philip Morris' estimate remains at $7.50, suggesting growth of 14.2% [15] - Over the past year, Altria stock gained 27.7%, underperforming Philip Morris, which increased by 36% [16] Investment Outlook - Philip Morris is viewed as the stronger growth story due to its transition to smoke-free products and efficiency initiatives, while Altria offers stability and consistent performance [17]

Core Viewpoint - Dividend stocks provide high yields and growth catalysts that can support payouts for decades, making them attractive for passive income investors [1][2]. Group 1: Dividend Stocks Overview - Building passive income through dividend-paying stocks allows investors to secure financial freedom by generating regular cash distributions [2]. - Dividend stocks combine income with potential long-term capital appreciation, offering protection against inflation through rising distributions [3]. Group 2: Company-Specific Insights - Philip Morris International offers a 3.6% yield with an 80% payout ratio, supported by its transformation towards smoke-free products, which generated 39% of 2024 revenue [6][7]. - Pfizer provides a 7.14% yield at 7.7 times forward earnings, with projected revenue of $61 billion to $64 billion in 2025, driven by various growth products and an acquisition of Metsera for up to $7.3 billion [8][9]. Group 3: Investment Considerations - Philip Morris trades at a discount with a forward earnings ratio of 19.4 compared to 22 for the S&P 500, while maintaining a credible path to smoke-free growth [7]. - Pfizer's high payout ratio of 90% presents execution risks, but management's commitment to dividends and lower expense guidance suggest a compelling risk-reward balance [9][11]. Group 4: Passive Income Strategy - Both Philip Morris and Pfizer offer different paths to passive income, with a combined yield of approximately 5.4%, significantly higher than the S&P 500 average [10]. - Sustainable yields backed by strong business fundamentals are crucial for passive income investing, with both companies demonstrating potential despite facing regulatory challenges [11].

Dividend Increase - Philip Morris International Inc. has raised its quarterly dividend by 8.9% to $1.47 per share, with the annualized dividend now totaling $5.88 per share, marking a total increase of 219.6% since 2008 [1][8] - The next dividend payment is scheduled for October 20, 2025, to shareholders on record as of October 3, 2025 [1] Growth Strategy - The company's long-term growth strategy is focused on its smoke-free transformation, with smoke-free products contributing 41% of total net revenues in Q2 2025, growing 15.2% year over year [2] - Key products driving this growth include IQOS, ZYN, and VEEV, positioning the company for sustainable growth and long-term value creation [2] Traditional Cigarette Business - Despite volume declines, the traditional cigarette business remains resilient, with combustible net revenues growing 2.1% in Q2, driven by price increases [3] - Marlboro achieved its highest quarterly market share since the 2008 spin-off, reinforcing the brand's strength and pricing leadership [3] Cost Efficiency Initiatives - The company achieved over $500 million in gross cost savings in the first half of the year through optimization initiatives, aiming for $2 billion in gross cost efficiencies between 2024 and 2026 [4] - By mid-2025, the company has already realized more than $1.2 billion in cost efficiencies, contributing to margin expansion [4] Earnings Outlook - Management has lifted its full-year adjusted earnings per share guidance to a range of $7.43-$7.56, indicating a growth of 13-15% [5] - This outlook reflects management's confidence in sustaining double-digit earnings growth despite ongoing regulatory and currency challenges [5] Stock Performance - Over the past six months, Philip Morris stock has risen 7.6%, compared to the industry's growth of 15.7% [10]

Group 1 - Philip Morris International Inc. (NYSE:PM) is recognized as one of the 15 best performing dividend stocks in 2025, with a stock surge of nearly 36% since the beginning of the year [1][3] - The company has successfully transitioned to next-generation, smoke-free products, such as IQOS heat-not-burn tobacco sticks and ZYN oral nicotine pouches, contributing to its stock performance [3] - Philip Morris has maintained a solid dividend policy, rewarding shareholders with growing dividends for the past 15 years, currently offering a quarterly dividend of $1.35 per share and a dividend yield of 3.31% as of September 15 [4] Group 2 - The company was established in 2007 after splitting from Altria, focusing on international markets where cigarette sales have been stronger [2] - In the second quarter, while cigarette sales volume decreased by 1.5%, organic revenue from cigarettes still grew by 2%, indicating resilience in its core business [2]

Core Insights - Altria Group, Inc. returned over $4 billion to shareholders in the first half of 2025 through dividends and share repurchases, demonstrating its strong cash-generating ability despite a challenging operating environment [1][8] Capital Return Strategy - Dividends are central to Altria's capital return strategy, with $3.5 billion distributed in the first half of 2025, reflecting the company's policy of returning the majority of earnings to shareholders [2] - Altria repurchased 10.4 million shares at an average price of $57.71, spending $600 million on buybacks, with $400 million remaining under its $1 billion share repurchase program [2][8] Financial Strength - Altria maintains a solid balance sheet, with a total debt-to-EBITDA ratio of 2.0x as of June 30, 2025, aligning with its financial targets and providing flexibility for shareholder returns [3][8] - The company's capital return strategy indicates management's confidence in its cash flow from tobacco and smoke-free products, reinforcing its position as a reliable income play in the consumer staples sector [4] Competitive Landscape - In contrast, Philip Morris International Inc. is focusing on smoke-free product expansion rather than capital returns, allocating resources to grow brands like IQOS, ZYN, and VEEV [5] - Turning Point Brands, Inc. reported a prudent financial position with total gross debt of $300 million and did not engage in share repurchases, focusing instead on market presence and product offerings [6] Valuation and Earnings Estimates - Altria's shares have decreased by 1.7% over the past month, compared to a 0.4% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 11.77X, lower than the industry average of 15.21X [10] - Zacks Consensus Estimates indicate year-over-year earnings growth of 5.3% for 2025 and 2.9% for 2026 [11]

Financial Data and Key Metrics Changes - The company reaffirmed its guidance for a 13% to 15% growth in EPS for the closing year [1] - The company reported its strongest growth since 2011, excluding the post-pandemic recovery [2] - There is an expectation of margin expansions this year, with previous hiccups in margins now behind [12] Business Line Data and Key Metrics Changes - Strong growth in IQOS and ZYN volumes, with ZYN already in 47 markets and expanding [5] - The company is experiencing positive volume growth in the tobacco and nicotine industry for five consecutive years [3] - The smoke-free product mix is contributing positively to both top-line revenue and gross margins [4][11] Market Data and Key Metrics Changes - The U.S. market is seeing intensified competition, particularly for ZYN, which has a price premium of over 65% compared to competitors [9][19] - The company is normalizing inventory levels after a period of stock limitations due to undercapacity [7] - The company is observing a strong pricing environment for combustible cigarettes, supported by a favorable tax environment [3] Company Strategy and Development Direction - The company is focused on smoke-free transformation and sees significant growth potential in this category [2][26] - There is a strategic emphasis on multi-category presence, including heat-not-burn, e-vape, and oral nicotine pouches [36] - The company is committed to continuous product innovation to meet evolving consumer expectations [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the smoke-free product category's growth potential, despite regulatory challenges in some markets [14][42] - The company anticipates that the competitive landscape will remain challenging but believes ZYN has a strong brand position [33] - Management noted that the currency environment is favorable, which supports the company's financial trajectory [57] Other Important Information - The EU is recognizing nicotine pouches for tax purposes, which is seen as a positive development for the company [44] - The company is awaiting regulatory approvals for IQOS in the U.S., with expectations leaning towards a 2026 launch [48] Q&A Session Summary Question: How should one think about ZYN shipment numbers for 2H '25? - Management suggested that shipment numbers should be based on sell-through growth rates applied to previous shipment figures [15][16] Question: What is the pricing strategy for ZYN given the competitive landscape? - Management acknowledged the high price premium of ZYN and indicated that marketing efforts would be ramped up to maintain market presence [20][21] Question: What is the outlook for IQOS growth in light of the flavor ban in Europe? - Management indicated that the flavor ban is being adjusted, and IQOS is expected to return to its growth trajectory [39] Question: How does the company view potential M&A opportunities? - Management stated that the company is currently self-sufficient and does not see immediate gaps in its product portfolio that would necessitate M&A [59][60] Question: What is the expected impact of the EU Tobacco Excise Directive? - Management noted that while the directive is being discussed, it is not expected to create major disruptions for the company's smoke-free product support [43][46]